Related Experiment Videos
Prevention and treatment of liver fibrosis based on pathogenesis
1Alcohol Research and Treatment Center, Bronx Veterans Affairs Medical Center and Mount Sinai School of Medicine, New York 10468, USA. liebercs@aol.com
Abstract:
Multiple agents have been proposed for the prevention and treatment of fibrosis. S-adenosylmethionine was reported to oppose CCl4-induced fibrosis in the rat, to attenuate the consequences of the ethanol-induced oxidative stress, and to decrease mortality in cirrhotics. Anti-inflammatory medications and agents that interfere with collagen synthesis, such as inhibitors of prolyl-4-hydroxylase and antioxidants, are also being tested. In nonhuman primates, polyenylphosphatidylcholine (PPC), extracted from soybeans, protected against alcohol-induced fibrosis and cirrhosis and prevented the associated hepatic phosphatidylcholine (PC) depletion by increasing 18:2 containing PC species; it also attenuated the transformation of stellate cells into collagen-producing transitional cells. Furthermore, it increased collagen breakdown, as shown in cultured stellate cells enriched with PPC or pure dilinoleoyl PC, the main PC species present in the extract. Because PPC and dilinoleoyl PC promote the breakdown of collagen, there is reasonable hope that this treatment may be useful for the management of fibrosis of alcoholic, as well as nonalcoholic, etiologies and that it may affect not only the progression of the disease, but may also reverse pre-existing fibrosis, as demonstrated for CCl4-induced cirrhosis in the rat and as presently tested in an ongoing clinical trial.
Insights
Polyenylphosphatidylcholine (PPC) shows promise in preventing and potentially reversing fibrosis. This soybean extract protects the liver from alcohol-induced damage and promotes collagen breakdown, offering hope for various fibrotic conditions.
Area of Science:
- Hepatology
- Fibrosis Research
- Biochemistry
Background:
- Fibrosis, a pathological scarring process, affects numerous organs and is associated with significant morbidity and mortality.
- Current therapeutic strategies for fibrosis are limited, necessitating the exploration of novel treatment agents.
- S-adenosylmethionine and anti-inflammatory agents are among those investigated for antifibrotic properties.
Purpose of the Study:
- To evaluate the efficacy of polyenylphosphatidylcholine (PPC) in preventing and treating liver fibrosis.
- To investigate the mechanisms by which PPC exerts its antifibrotic effects.
- To explore the potential of PPC in managing both alcoholic and nonalcoholic fibrotic liver diseases.
Main Methods:
- Administration of PPC to nonhuman primates exposed to alcohol to assess protection against fibrosis and cirrhosis.
- Analysis of hepatic phosphatidylcholine (PC) species to understand PPC's impact on lipid metabolism.
- In vitro studies using cultured stellate cells to examine PPC's effect on collagen synthesis and breakdown.
Main Results:
- PPC protected nonhuman primates from alcohol-induced fibrosis and cirrhosis.
- PPC prevented hepatic phosphatidylcholine depletion by increasing specific PC species.
- PPC attenuated the transformation of hepatic stellate cells and increased collagen breakdown in vitro.
Conclusions:
- Polyenylphosphatidylcholine (PPC) demonstrates significant potential in preventing and treating liver fibrosis.
- PPC's mechanisms involve modulating lipid metabolism, inhibiting stellate cell activation, and promoting collagen degradation.
- PPC may offer a therapeutic option for diverse fibrotic etiologies, potentially reversing existing fibrosis.